Founded in 2008, we are a privately-held biotech company and we work with big pharma, biotech and academia across the world. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.

To study pre-clinical models of neurodegeneration we have developed an innovative pipeline for quantitative whole brain imaging. By combining light sheet microscopy, AI powered image analysis and cloud-based data reporting it is possible to count single cells, plaques or quantify drug distribution. To try it out click on the Gubra 3D experience below.